Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK, Idenix Ink Collaboration

by Rick Mullin
February 16, 2009 | A version of this story appeared in Volume 87, Issue 7

GlaxoSmithKline has agreed to pay Cambridge, Mass.-based Idenix up to $450 million in a licensing agreement that will give GSK exclusive worldwide rights to IDX899, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development for treatment of HIV/AIDS. IDX899 is being developed to address the increasing prevalence of viral resistance and side effects in the NNRTI drug class. Under the terms of the agreement, GSK will pay Idenix $34 million up front and as much as $416 million in development, regulatory, and sales milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.